412 results about "Arachidonic acid supplementation" patented technology

The present invention relates to a process for preparing a biomass, such as from a microbial fermentation, for an extraction process to separate desired chemicals, nutritional products, bioactive components, proteins, carbohydrates, and lipids, from the biomass. Particularly preferred substances to extract include docosahexaenoic acid, docosapentaenoic acid, and arachidonic acid. The present invention also includes extracting the prepared biomass. Biomasses to be treated in accordance with the methods of the invention include plant, animal, and microbial biomass, particularly a microorganism such as Crypthecodinium cohnii and a fungus such as Mortierella alpina.

Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts to enable synthesis and high accumulation of ARA. Production host cells are claimed, as are methods for producing ARA within said host cells.

The present inventions relate to therapeutic compositions comprising, and methods utilizing, arachidonic acid derivatives and analogs for treatment of patients demonstrating symptoms of pathological conditions. Specifically, the inventions relate to therapeutic compositions for activating transient receptor potential vanilloid-1 channels (TRPV1). Additionally, therapeutic compositions are provided for increasing TRPV1-type responses. These pathological conditions include, but are limited to, hypertension, in particular salt induced hypertension, and cardiovascular complications, including myocardial infarction, kidney dysfunction, diabetes, and inflammation. Further, the inventions relate to drug screening methods for providing additional therapeutic compounds.

A nutrition bar comprising about 10% wt or more of soy and/or rice protein, at least one transition metal or transition metal compound, and about 2% wt or more of a humectant, and wherein the at least one transition metal or transition metal compound is in a substantially water insoluble form at 20° C. or the nutrition bar has an Aw of 0.45 or less or about 1% wt or more of the soy and/or rice protein is in the form of nuggets and the humectant is selected from polyols. The bars have elevated levels of soy and/or rice protein, yet do not suffer unacceptable from a deterioration in taste or other organoleptic properties over time. In other aspects, a nutrition bar or other food which incorporates pro-oxidants and/or polyunsaturated fatty acids or their sources in encapsulated form, especially as microcapsules. The pro-oxidants may be metal salts such as copper, manganese, iron and/or zinc salts. Sources of omega-3 fatty acids include fish oil. Processes for preparing the polyunsaturated fatty acid capsules are also disclosed. The polyunsaturated fatty acid capsules/microcapsules are prepared by forming an emulsion of the unsaturated fatty acid with a carrier, spray drying the emulsion to form a powder and encapsulating powder, especially with a fluid bed. The invention is especially useful for encapsulating polyunsaturated fatty acids, or oil sources thereof, most preferably omega-3 and omega-6 fatty acids, such as arachidonic acid, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), lineoleic acid, linolenic acid (alpha linolenic acid), and gamma-linolenic acids, fish oil, and oil sources of C18:2 and C18:3 fatty acids such as canola oil, soybean oil or blends thereof.

The invention relates to an anti-inflaming infant formula milk powder and a preparation process thereof. The anti-inflaming infant formula milk powder comprises the following components in percentage by weight: 22%-50% of lactose, 10%-20% of goat milk whey protein concentrate, 9.8%-20% of structural grease 1,3-dioleoyl 2-palmitoyl triglyceride, 10%-13.5% of non-fat goat milk powder, 8%-10% of vegetable oil, 2%-8% of beta-casein, 0.8%-1.6% of fructooligosaccharides, 0.5%-1.5% of mineral premix, 0.3%-1% of galactooligosaccharide, 0.2%-1% of immunoglobulin G, 0.2%-0.5% of lactulose, 0.10%-0.45% of arachidonic acid, 0.1%-0.6% of docosahexaenoic acid, 0.06%-0.12% of vitamin premix, 0.04%-0.06% of lactoferrin, and 0.01%-0.06% of nucleotide. The invention also includes the preparation process ofthe infant formula milk powder. The nutrition constituents and the functions of the infant formula milk powder are close to those of breast milk, the infant formula milk powder is easy to assimilate,and infants do not get inflamed after eating the milk powder.

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated acids (i.e., "elongases") and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to omega3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, omega6-docosapentaenoic acid or omega3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

A method of treating a neurological disorder comprises administering to a person affected from such a disorder a microbial oil comprising DHA, a microbial oil comprising ARA or a combination of DHA and ARA oils in an amount sufficient to elevate the levels of circulating DHA and/or ARA in the person's blood to at least normal levels.

The production and use, and in particular, the extraction, separation, synthesis and recovery of polar lipid-rich fractions containing eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA(n-3) or DPA(n-6)), arachidonic acid (ARA), and eicosatetraneonoic acid (C20:4n-3) from microorganisms, genetically modified seeds and marine organisms (including fish and squid) and their use in human food applications, animal feed, pharmaceutical applications and cosmetic applications.

The invention discloses a formula milk powder for promoting the absorption of fatty acid and calcium and a preparation method thereof. Raw cow milk, lactose, 1,3-Dioleoyl 2-palmitoyl triglyceride and demineralized whey powder as main materials are added with concentrated whey albumen powder, Alpha-lactalbumin powder, oligosaccharide, walnut oil, casein phosphopeptide, docosahexaenoic acid, arachidonic acid, nucleotide, lutein, inositol, carnitine and the like as well as vitamins, mineral substances and other nutrients needed for strengthening infants, and fat humanization, protein humanization and carbohydrate humanization are realized. The powdery product is produced by the processes of blending, homogenization, concentration, spray-drying, packaging and the like. According to the physiological characteristics and nutritional demand of the infants, the invention reinforces the calcium, the 1,3-Dioleoyl 2-palmitoyl triglyceride, other nutrient ingredients and the like, and aiming at the oversea clinical test conclusion of the 1,3-Dioleoyl 2-palmitoyl triglyceride, the final test conclusion of comparison with breast milk and infant formula milk powder sold on the market in the process of a clinical feeding test is that the feeding result of the designed formula approximates the feeding result of the breast milk and is better than the feeding result of an infant formula milk powder group sold on the market.

The invention relates to a method for the production of arachidonic acid in transgenic organisms, especially in transgenic plants and yeasts. The invention also relates to DNA sequences coding for a protein with enzymatic activity of a Δ5-desaturase from Phytophthera megasperma. The invention further relates to transgenic plants and plant cell and transgenic yeasts containing a nucleic acid molecule comprising a DNA sequence according to the present invention and having, on the basis thereof, an enhanced arachidonic acid synthesis in comparison with wild-type cells. The invention also relates to harvest products and propagating material of transgenic plants.

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “Δ9-elongase”) and to uses thereof. In particular, Δ9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-γ-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-γ-linolenic acid (DGLA, 20:3n-6) is then catalyzed by Δ8-desaturase and Δ5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

The invention relates to a nutritional blend oil with balanced fatty acid components and active components for the middle and old aged, which is prepared by a plurality of plant oils selected from flaxseed oil, walnut oil, double-low rapeseed oil, soybean oil, wheat germ oil, corn oil, teal oil, peanut oil, grape seed oil, rice bran oil, camellia oil, evening primrose seed oil, sunflower seed oil and the like, wherein, Omega 6 serial polyunsaturated fatty acids (PUFA) and Omega 3 serial PUFA are contained to enable the ratio of saturated fatty acid (SFA) to monounsaturated fatty acid (MUFA) to PUFA to be 0.6-0.8:1:1, the ratio of Omega 6 to Omega 3 to be 4:1 in the comprehensive evaluation of the blend oil absorbed by the middle and old aged and the fat from other sources, thereby meeting the recommended value of Chinese Nutrition Society; the nutritional blend oil contains 2% of gama-linolenic acid, thereby beneficial to improving the contents of DH-gama-linolenic acid and arachidonic acid; the total content of lauric acid, myristic acid and palmitic acid contained in the nutritional blend oil is below 8.5% in order to avoid over rising the level of Low density lipoprotein (LDL) in the plasm of the middle and old aged; in addition, the nutritional blend oil also comprises a plurality of active components with oxidation resistant property, so other antioxidants do not need to be added in the blend oil.The blend oil provided by the invention is characterized by low cost, balanced fatty acid nutrition, a plurality of abundant active components and higher security, thereby better improving the health and intelligence of eaters, preventing cardiovascular and cerebrovascular diseases, and avoiding fatness, hyperlipidemia, thrombotic diseases and the like caused by unbalanced fatty nutrition.

The invention discloses infant formula milk powder added with secretory immunoglobulin A and a preparation method thereof. The infant formula milk powder consists of demineralized whey powder, defatted milk powder, mixed vegetable oil, milk sugar, mineral substance premix, lecithin, arachidonic acid, lactulose, fructooligosaccharides, oligosaccharide, water soluble vitamin premix, secretory immunoglobulin A, calcium hydroxide, citric acid, docosahexenoic acid, milk phosphatide, lactoferrin, soyabean lecithin, liposoluble vitamin premix, nucleotide and L-carnitine. The invention also discloses a method for preparing the infant formula milk powder. The infant formula milk powder has important effects of improving infant immunologic function, preventing allergy and preventing mucous membrane infection. The provided secretory immunoglobulin A fluidized bed low-temperature addition technology contributes to effectively guaranteeing the activity of immunity substances.

Arachidonic acid and/or compounds containing arachidonic acid as a constituent fatty acid are used to obtain compounds which prevent decline of, improve or enhance normal responses of cognitive abilities of a healthy person, and which are highly suitable for pharmaceuticals as well as food products, with minimal side effects.

The invention provides goat milk powder for an infant. The goat milk powder is prepared from the following raw materials in parts by weight: 18 to 30 parts of skim goat milk powder, 5 to 10 parts of corn syrup solid, 5 to 12 parts of whole goat milk powder, 4 to 8 parts of special grease, 1.0 to 1.6 parts of fructo-oligosaccharide, 1.0 to 1.6 parts of galactooligosaccharide, 10 to 25 parts of vegetable oil, 25 to 40 parts of milk sugar, 14 to 24 parts of concentrated goat whey protein powder, 0.5 to 1.2 parts of alpha-whey protein, 0.2 to 0.4 part of DHA, 0.2 to 0.5 part of arachidonic acid, 0.12 to 0.16 part of vitamin premix, 0.4 to 0.9 part of mineral substance premix, 0.0004 to 0.01 part of L-carnitine, 0.01 to 0.03 part of taurine and 0.02 to 0.04 part of nucleotide, wherein the special grease is triglyceride with the ratio of 50 to 70 percent, on the Sn-2 position, of palmitic acid. According to the goat milk powder provided by the invention, effort is further made for enabling the formula goat milk powder to be more like breast milk, so that the absorption of the infant to nutrients in the milk powder is more comprehensive, and the probability of dyspepsia and easiness in getting inflamed and diarrhea of the infant is further reduced.

The invention concerns a method for stimulating intestinal barrier integrity in a patient infected with HIV by administering to said patient composition comprising: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic acid (ARA), and at least two distinct oligosaccharides.

The invention is directed to compositions comprising lecithin, olive oil, esterified fatty acids and mixed tocophenols for use in the treatment and prevention of various types of arthritis and other inflammatory joint conditions, periodontal diseases and psoriasis, which avoid many of the side effects associated with known treatments. The compositions of the present invention have the advantage of increased stability, a reduction of arachidonic acid in cells, a reduction in eicosanoid production and enhanced cell regulation and communication. Also disclosed are methods for using the compositions for treatment and prevention.

The present invention belongs to the technical field of feed, and specifically discloses a functional fat feed additive and a preparation method thereof. The functional fatty feed additives mainly comprise the following components in parts by weight: linoleic acid 15-25 parts, arachidonic acid, 2-10 parts, alpha-linolenic acid 8-10 parts, eicosapentaenoic acid 5-10 parts, docosahexaenoic acid 5-10 parts, docosapentenoic acid 2-8 parts, and vitamin C1 1-5 parts. The omega-6 and omega-3 polyunsaturated fatty acid are used to prepare a fat feed additive microcapsule by applying the microencapsulation technique, which not only improves the addition ratio of omega-3 polyunsaturated fatty acid of the daily ration, but also maintains a suitable ratio between omega-6 and omega-3 polyunsaturated fatty acids of the daily ration, makes full use of the nutritional efficacies of omega-6 and omega-3 polyunsaturated fatty acids, improves the immunity of animals, and improves the growth and reproductive performance of animals.